Nov 21, 2025 • The Globe and Mail
BULLISH
CLSA Reaffirms Their Buy Rating on BeiGene Ltd (6160)
CLSA analyst Matthew Yan has reaffirmed a Buy rating on BeiGene Ltd (6160) with a price target of HK$288.00. This comes after the company reported strong financial results for the quarter ending June 30, including a quarterly revenue of HK$1.32 billion and a net profit of HK$94.32 million. Yan has a good track record in the Healthcare sector, and the consensus among analysts for BeiGene Ltd is a Strong Buy.
Nov 18, 2025 • The Globe and Mail
BULLISH
UBS Keeps Their Buy Rating on BeiGene Ltd (6160)
UBS has maintained a Buy rating on BeiGene Ltd (HKEX: 6160) with a price target of HK$262.20. This rating is supported by another Buy rating from CLSA, despite a Hold rating from TR | OpenAI – 4o. BeiGene Ltd reported strong quarterly results for the period ending June 30, with revenues of HK$1.32 billion and a net profit of HK$94.32 million.
Nov 10, 2025 • The Globe and Mail
BULLISH
Morgan Stanley Sticks to Their Buy Rating for BeiGene Ltd (6160)
Morgan Stanley reiterated a Buy rating on BeiGene Ltd (6160) on November 6, setting a price target of HK$234.00. The analyst consensus for BeiGene Ltd is a Strong Buy with an average price target of HK$252.26, indicating a significant upside. The company recently reported a quarterly revenue of HK$1.32 billion and a net profit of HK$94.32 million, showing growth compared to the previous year.
May 29, 2025 • Simply Wall Street
BULLISH
BeOne Medicines (Nasdaq:ONC) - Stock Analysis
BeOne Medicines (Nasdaq:ONC) is an oncology company specializing in cancer treatments, with a current market cap of US$34.4 billion. The stock is trading at a significant discount to its estimated fair value and is projected to experience substantial earnings growth of 46.51% per year. Despite recent insider selling, analysts largely agree on a positive future price trajectory for the company.
May 14, 2025 • Business Wire
BULLISH
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
BeiGene announced it will present 31 abstracts, including four oral presentations, at EHA 2025, showcasing data from its BTK inhibitor BRUKINSA and investigational pipeline assets sonrotoclax and BGB-16673. The data reinforce BRUKINSA's efficacy and safety in CLL and highlight promising clinical activity and safety profiles for sonrotoclax and BGB-16673 across various B-cell malignancies. These presentations underscore BeiGene's commitment to advancing targeted therapies and redefining the standard of care in hematology.
Aug 17, 2023 • Wiley Online Library
BULLISH
The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer
This study examined the health-related quality of life (HRQoL) in patients with advanced non-small cell lung cancer (NSCLC) treated with tislelizumab versus docetaxel in the RATIONALE-303 trial. Patients receiving tislelizumab showed improved HRQoL and reduced lung cancer symptoms like fatigue and coughing compared to those on docetaxel. The findings support tislelizumab's favorable risk-benefit ratio as a second-line therapy for NSCLC.